Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Cash: 2019-2025

Historic Change in Cash for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $106.3 million.

  • Avidity Biosciences' Change in Cash rose 151.69% to $106.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.0 million, marking a year-over-year decrease of 106.98%. This contributed to the annual value of $37.3 million for FY2024, which is 124.01% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Change in Cash is $106.3 million, which was up 1,132.26% from -$10.3 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Change in Cash high stood at $286.3 million for Q1 2024, and its period low was -$221.7 million during Q1 2023.
  • Over the past 3 years, Avidity Biosciences' median Change in Cash value was $34.3 million (recorded in 2025), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Avidity Biosciences' Change in Cash soared by 1,281.79% in 2021, and later tumbled by 796.21% in 2022.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Change in Cash stood at -$89.6 million in 2021, then soared by 319.61% to $196.7 million in 2022, then plummeted by 49.45% to $99.4 million in 2023, then slumped by 251.18% to -$150.3 million in 2024, then soared by 151.69% to $106.3 million in 2025.
  • Its Change in Cash stands at $106.3 million for Q3 2025, versus -$10.3 million for Q2 2025 and $34.3 million for Q1 2025.